Back to Journals » OncoTargets and Therapy » Volume 14

High VCAM-1 Predicts Poor Prognosis and is Associated with Chemotherapy Resistance in Nasopharyngeal Carcinoma

Authors Huang Y, Miao H, Xia C, Feng H, Xu S, Liang Z, Wang Y, Zhao C, Qin G, Ou X, Zhao F

Received 15 November 2020

Accepted for publication 16 February 2021

Published 2 March 2021 Volume 2021:14 Pages 1633—1641


Checked for plagiarism Yes

Review by Single anonymous peer review

Peer reviewer comments 2

Editor who approved publication: Prof. Dr. Geoffrey Pietersz

Yu Huang,1,* Hongbin Miao,2,* Chenxi Xia,1,* Huajun Feng,1 Shengen Xu,1 Zhuoping Liang,1 Yuanyuan Wang,1 Chong Zhao,1 Gang Qin,1 Xiaoyi Ou,1 Feipeng Zhao1

1Department of Otolaryngology-Head and Neck Surgery, The Affiliated Hospital of Southwest Medical University, Southwest Medical University, Luzhou, 646000, Sichuan, People’s Republic of China; 2Department of Otolaryngology-Head and Neck Surgery, The People’s Hospital of Bishan District, Chongqing Medical University, Bishan, 402760, Chongqing, People’s Republic of China

*These authors contributed equally to this work

Correspondence: Xiaoyi Ou; Feipeng Zhao
Department of Otolaryngology-Head and Neck Surgery, The Affiliated Hospital of Southwest Medical University, No. 25 Taiping Street, Luzhou, 646000, Sichuan Province, People’s Republic of China
Tel +86-830-3165641
Fax +86-830-2392753
Email [email protected]; [email protected]

Purpose: Nasopharyngeal carcinoma (NPC) is a malignant tumor endemic in southern China and Southeast Asia with a poor prognosis. Vascular cell adhesion protein 1 (VCAM-1) is highly expressed in NPC; however, it is unclear whether VCAM-1 is correlated with chemotherapy resistance and prognosis in NPC.
Patients and Methods: To further explore the role of VCAM-1 in chemotherapy resistance and prognosis in NPC, we examined the expression of VCAM-1, the sensitivity of chemotherapy drugs, and clinical follow-up data from 73 patients with NPC. Then, the results of VCAM-1 expression were analyzed in response to chemotherapy drugs, progression-free survival (PFS), and overall survival (OS).
Results: The expression of VCAM-1 protein in NPC was significantly higher than that in chronic inflammatory tissue. No significant differences in the expression of VCAM-1 among gender, age, pathologic classification, tumor classification, lymph node status, metastasis status, and overall clinical stage were found. The periods of PFS and OS in patients with high VCAM-1 expression were significantly shorter than those in patients with low VCAM-1 expression. The sensitivity rates of NPC to eight chemotherapy drugs were different; carboplatin and docetaxel showed the highest chemotherapy sensitivity and resistance rates, respectively. The resistance rates to paclitaxel were different between the patients with high VCAM-1 expression and those with low VCAM-1 expression.
Conclusion: Our data indicated that VCAM-1 was highly expressed in NPC. Patients with high VCAM-1 expression were more prone to shorter periods of PFS and OS. VCAM-1 could be a prognostic marker of NPC patients. The detection of VCAM-1 expression in NPC may be valuable for chemotherapy drug evaluation and management of patients with NPC in the clinic.

Keywords: nasopharyngeal carcinoma, VCAM-1, prognosis, chemotherapy resistance

Creative Commons License This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.

Download Article [PDF]  View Full Text [HTML][Machine readable]